Launch of Ulcerative Colitis and Crohn's Disease Therapeutic Agent Pentasa Tablets 500
October 1, 2008
KYORIN Co., Ltd. Announces that its wholly owned subsidiary, KYORIN Pharmaceutical Co., Ltd.(Headquarters :Tokyo, President :Itaru Kojo) launched today Pentasa® Tablets 500 as an additional formulation to the Pentasa®250 (generic name :mesalazine) already on the market.
Since July 1996, KYORIN Pharmaceutical Co., Ltd. and Nisshin Kyorin Pharmaceutical Co., Ltd. both have marketed Pentasa® Tablets 250 and have contributed to the treatment of ulcerative colitis and Crohn's disease.
Pentasa® Tablets 500 lessen the burden on patients by reducing the number of tablets currently marketed Pentasa® Tablets 250 that are administered per day. Pentasa® Tablets 500 were developed for the purpose of improving adherence as well as QOL.
To distinguish them from the round Pentasa® Tablets 250, Pentasa® Tablets 500 came in a capsule form.
Inflammatory bowel diseases (ulcerative colitis and Crohn's disease) are intractable diseases that hinder social interaction, causing frequent diarrhea and melena. The causes have not been identified and there is no radical treatment. Therefore, the therapeutic goals are suppressing symptoms in the active phase, alleviating the symptoms and keeping the symptoms in a relieved state with the use of mesalazine drugs like Pentasa and steroids.
On October 1, 2008, KYORIN Pharmaceutical Co., Ltd. merged Nisshin Kyorin Pharmaceutical Co., Ltd. into KYORIN Pharmaceutical Co., Ltd. we will exclusively market Pentasa® Tablets 250, Pentasa® Enema 1g and Pentasa® Tablets 500 and will make an ongoing contribution to the treatment of inflammatory bowel diseases by providing the latest information, including peripheral information.
Adobe Reader software is required to view and print PDF files. The latest version of Adobe Reader can be downloaded by accessing the Adobe Systems Incorporated website.